Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 13/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314066 | 0.83 | MAP2 (0.49) | MAP2SIRT1KDM4EALDH1A1 | |
| SCHEMBL4310084 | 0.81 | MAP2 (0.47) | MAP2SIRT1KDM4EALDH1A1 | |
| SCHEMBL4312754 | 0.80 | MAP2 (0.46) | MAP2SIRT1KDM4EALDH1A1 | |
| SCHEMBL2347447 | 0.78 | MAP2 (0.59) | MAP2SIRT1 | |
| SCHEMBL4315896 | 0.77 | MAP2 (0.48) | MAP2SIRT1 | |
| SCHEMBL4317335 | 0.77 | MAP2 (0.50) | MAP2SIRT1 | |
| SCHEMBL2352924 | 0.75 | MAP2 (0.51) | MAP2SIRT1KDM4EALDH1A1 | |
| SCHEMBL4319804 | 0.75 | MAP2 (0.48) | MAP2SIRT1 | |
| SCHEMBL8938304 | 0.74 | MAP2 (0.59) | MAP2 | |
| SCHEMBL4319380 | 0.74 | MAP2 (0.47) | MAP2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131494-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-21 | — | — | US | claimed |
| EP-1915055-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-30 | — | — | EP | claimed |
| WO-2007021629-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131494-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | IDO1, IDO2, INMT | MAP2 1220/4885SIRT1 699/4885KDM4E 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.